[A23-104] Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2024
Project no.:
A23-104
Commission:
Commission awarded on 31.10.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Postmenopausal women, and men, with oestrogen receptor positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor
- Postmenopausal women: added benefit not proven
- Men: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-104_en
| Project no. | Title | Status |
|---|---|---|
| A24-30 | Elacestrant (breast cancer) – Addendum to Project A23-104 | Commission completed |
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.